Article info

Download PDFPDF

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Authors

  1. Correspondence to Dr David SP Tan, Cancer Science Institute, National University of Singapore and National University Cancer Institute, SIngapore, National University Health System, Singapore 119074, Singapore; david_sp_tan{at}nuhs.edu.sg
View Full Text

Citation

Ngoi NY, Heong V, Ow S, et al
A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Publication history

  • Accepted June 3, 2020
  • First published June 25, 2020.
Online issue publication 
August 03, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.